ArticleAmerican journal of translational research2025
Predictive role of inflammatory markers in characterizing the progression of interstitial lung disease: a retrospective analysis.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Baseline neutrophil-to-lymphocyte ratio predicts survival time after the initiation of nintedanib in patients with interstitial lung disease.BMC pulmonary medicine · 2026Article
- Linear association between the systemic immune-inflammation index and all-cause mortality in patients with interstitial lung disease: a retrospective cohort study.Frontiers in medicine · 2026Article
- Construction and validation of a machine learning model integrating ultrasound features and inflammatory markers (OVART-ML) for predicting ovarian torsion and ischemic necrosis risk in children.Frontiers in pediatrics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate the association between inflammatory markers and interstitial lung disease (ILD) progression in order to enhance disease monitoring and risk stratification.
methodsThis retrospective cohort study analyzed the clinical data from 172 ILD patients admitted to Nanjing Jiangbei Hospital between January 2021 and December 2023. Patients were categorized into two groups: progressive ILD (PILD; n=95) and rapidly progressive ILD (RPILD; n=77), based on changes in symptoms and pulmonary function within six months. PILD was defined by a ≥10% relative decline in predicted Forced Vital Capacity (ppFVC) or related clinical criteria. RPILD was defined by acute symptom worsening and significant pulmonary function deterioration. Inflammatory markers assessed included C-reactive protein (CRP), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), and systemic immune-inflammation index (SII).
resultsCRP, NLR, PLR, and SII levels were significantly higher in the RPILD group, while LMR was significantly lower (all P<0.05). Multivariate logistic regression identified CRP, NLR, LMR, and SII as independent predictors of ILD progression. ROC analysis showed NLR had the highest individual predictive value (AUC=0.757). A composite model combining all five markers achieved an AUC of 0.842, indicating improved predictive accuracy.
conclusionsInflammatory markers, particularly NLR, are independently associated with ILD progression. A composite model incorporating multiple markers offers enhanced predictive performance, potentially supporting clinical decision-making and early intervention strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.